Biodel to Report Fourth Quarter Fiscal Year 2010 Financial Results on December 9, 2010

DANBURY, Conn., Dec. 6, 2010 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) will issue its fourth quarter fiscal year 2010 financial results on December 9, 2010. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.

December 9, 2010 schedule:

4:00 pm EST:

Q4 fiscal year 2010 results will be


4:15 pm EST:

Conference call participants should dial:

+1 ( 877 ) 303 - 8028 (United States) or

+1 ( 760 ) 536 - 5167 (International)

4:30 pm EST:

Conference call begins

Interested parties may access a live audio webcast of the conference call in the investor section of Biodel's website at The audio webcast will be archived and available for replay through the website.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes. Biodel's product candidates are developed using VIAdel™ technology, which reformulates existing FDA-approved peptide drugs. Linjeta™ is Biodel's most advanced product candidate and has been reviewed by the FDA which issued a complete response letter. Earlier-stage product candidates include VIAtab™, a sublingual tablet formulation of insulin, a line of basal insulins, and a stabilized formulation of glucagon. For further information regarding Biodel, please visit the company's website at


The Trout Group LLC

Seth D. Lewis, +1-646-378-2952

SOURCE Biodel Inc.